Freeline Therapeutics Holdings plc Research and Development Expense
Freeline Therapeutics Holdings plc reported Research and Development Expense of $25.51 million for the 9-month period ending 2023-09-30, per its 6-K filed 2023-12-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2023-12-01
- Freeline Therapeutics Holdings plc research and development expense for the quarter ending 2023-09-30 was $5.79M, a 60.83% decline year-over-year.
- Freeline Therapeutics Holdings plc research and development expense for the quarter ending 2023-06-30 was $8.83M, a 53.14% decline year-over-year.
- Freeline Therapeutics Holdings plc research and development expense for the quarter ending 2023-03-31 was $10.89M, a 45.39% decline year-over-year.
- Freeline Therapeutics Holdings plc research and development expense for the quarter ending 2022-12-31 was $12.64M, a 48.62% decline year-over-year.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2023-09-30 | $5.79M derived: 6-K 9 month − 6-K 6 month · filed 2023-12-01 | $14.62M derived: sum of 2 quarters · filed 2023-12-01 | $25.51M 6-K · filed 2023-12-01 | $38.15M derived: sum of 4 quarters · filed 2023-12-01 |
| 2023-06-30 | $8.83M derived: 6-K 6 month − 6-K 3 month · filed 2023-08-15 | $19.72M 6-K · filed 2023-08-15 | $32.36M derived: sum of 3 quarters · filed 2023-08-15 | $47.14M derived: sum of 4 quarters · filed 2023-12-01 |
| 2023-03-31 | $10.89M 6-K · filed 2023-05-30 | $23.54M derived: sum of 2 quarters · filed 2023-05-30 | $38.31M derived: sum of 3 quarters · filed 2023-12-01 | $57.15M derived: sum of 4 quarters · filed 2023-12-01 |
| 2022-12-31 | $12.64M derived: 20-F 12 month − 6-K 9 month · filed 2023-04-04 | $27.42M derived: sum of 2 quarters · filed 2023-12-01 | $46.26M derived: sum of 3 quarters · filed 2023-12-01 | $66.20M 20-F · filed 2023-04-04 |
| 2022-09-30 | $14.78M derived: 6-K 9 month − 6-K 6 month · filed 2023-12-01 | $33.61M derived: sum of 2 quarters · filed 2023-12-01 | $53.56M 6-K · filed 2023-12-01 | $78.17M derived: sum of 4 quarters · filed 2023-12-01 |
| 2022-06-30 | $18.84M derived: 6-K 6 month − 6-K 3 month · filed 2023-08-15 | $38.78M 6-K · filed 2023-08-15 | $63.39M derived: sum of 3 quarters · filed 2023-08-15 | $86.08M derived: sum of 4 quarters · filed 2023-08-15 |
| 2022-03-31 | $19.95M 6-K · filed 2023-05-30 | $44.55M derived: sum of 2 quarters · filed 2023-05-30 | $67.25M derived: sum of 3 quarters · filed 2023-05-30 | $91.52M derived: sum of 4 quarters · filed 2023-05-30 |
| 2021-12-31 | $24.60M derived: 20-F 12 month − 6-K 9 month · filed 2023-04-04 | $47.30M derived: sum of 2 quarters · filed 2023-04-04 | $71.57M derived: sum of 3 quarters · filed 2023-04-04 | $95.43M 20-F · filed 2023-04-04 |
| 2021-09-30 | $22.70M derived: 6-K 9 month − 6-K 6 month · filed 2022-11-15 | $46.96M derived: sum of 2 quarters · filed 2022-11-15 | $70.83M 6-K · filed 2022-11-15 | $91.71M derived: sum of 4 quarters · filed 2023-04-04 |
| 2021-06-30 | $24.27M derived: 6-K 6 month − 6-K 3 month · filed 2022-08-09 | $48.13M 6-K · filed 2022-08-09 | $69.01M derived: sum of 3 quarters · filed 2023-04-04 | $94.84M derived: sum of 4 quarters · filed 2023-04-04 |
| 2021-03-31 | $23.86M 6-K · filed 2022-05-10 | $44.74M derived: sum of 2 quarters · filed 2023-04-04 | $70.57M derived: sum of 3 quarters · filed 2023-04-04 | $82.56M derived: sum of 4 quarters · filed 2023-04-04 |
| 2020-12-31 | $20.88M derived: 20-F 12 month − 6-K 9 month · filed 2023-04-04 | $46.70M derived: sum of 2 quarters · filed 2023-04-04 | $58.69M derived: sum of 3 quarters · filed 2023-04-04 | $76.15M 20-F · filed 2023-04-04 |
| 2020-09-30 | $25.82M derived: 6-K 9 month − 6-K 6 month · filed 2021-11-09 | $37.81M derived: sum of 2 quarters · filed 2021-11-09 | $55.27M 6-K · filed 2021-11-09 | |
| 2020-06-30 | $11.99M derived: 6-K 6 month − 6-K 3 month · filed 2021-08-16 | $29.45M 6-K · filed 2021-08-16 | ||
| 2020-03-31 | $17.46M 6-K · filed 2021-05-17 | |||
| 2019-12-31 | $47.04M 20-F · filed 2022-03-31 | |||
| 2019-06-30 | $23.62M 6-K · filed 2020-10-29 | |||
| 2018-12-31 | $34.19M 20-F · filed 2021-03-31 |